Find Clinical Trials & Studies

Visit the Research & Education Institute

Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated ES-SCLC

I'm Interested!

Please call
1-800-641-2422

A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Sex: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Lung

Study Purpose

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (ES-SCLC). The primary objectives of this study are to compare the effect of SG to SOC on overall survival (OS).

Principal Investigator
Afshin Dowlati MD

Department/Division
Cancer (Thoracic)

UH IRB: STUDY20250088 Pro00085679
StudyID: GSI1525
ClinicalTrials.gov: NCT06801834

I'm Interested!

Please call
1-800-641-2422

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422